Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in
patients with metastatic colorectal cancer refractory to standard chemotherapies.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd